News
-
-
PRESS RELEASE
EQS-Adhoc: Marinomed Biotech AG resolves second capital increase excluding statutory subscription rights by issuing 83,750 no-par value bearer shares at an issue price of EUR 8 per share
Marinomed Biotech AG resolves second capital increase by issuing 83,750 bearer shares at EUR 8 per share, excluding subscription rights -
-
PRESS RELEASE
EQS-Adhoc: Marinomed Biotech AG: Binding Term Sheet for the intended issuance of a convertible bond to the European Investment Bank (EIB) signed
Marinomed Biotech AG signs Binding Term Sheet with European Investment Bank for convertible bond issuance. Convertible bond to be issued in December 2024 -
-
PRESS RELEASE
EQS-Adhoc: Marinomed Biotech AG: Publication of a report on the exclusion of subscription rights for a possible second cash capital in-crease of up to 154,053 shares
Marinomed Biotech AG plans a possible second cash capital increase and will publish a report on the exclusion of subscription rights. Negotiations ongoing with investors -
-
-
-
PRESS RELEASE
EQS-Adhoc: Marinomed Biotech AG signs agreement for sale of Carragelose business to French Unither Pharmaceuticals
Marinomed Biotech AG signs agreement to sell Carragelose business to Unither Pharmaceuticals, facilitating refinancing and focus on Marinosolv. Agreement subject to various conditions
